Literature DB >> 22425895

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.

T Bains, M C Heinrich, M M Loriaux, C Beadling, D Nelson, A Warrick, T L Neff, J W Tyner, J Dunlap, C L Corless, G Fan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22425895     DOI： 10.1038/leu.2012.74

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  32 in total

Review 1.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

2.  Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.

Authors:  Joachim B Kunz; Tobias Rausch; Obul R Bandapalli; Juliane Eilers; Paulina Pechanska; Stephanie Schuessele; Yassen Assenov; Adrian M Stütz; Renate Kirschner-Schwabe; Jana Hof; Cornelia Eckert; Arend von Stackelberg; Martin Schrappe; Martin Stanulla; Rolf Koehler; Smadar Avigad; Sarah Elitzur; Rupert Handgretinger; Vladimir Benes; Joachim Weischenfeldt; Jan O Korbel; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

3.  Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Authors:  M Kontro; H Kuusanmäki; S Eldfors; T Burmeister; E I Andersson; O Bruserud; T H Brümmendorf; H Edgren; B T Gjertsen; M Itälä-Remes; S Lagström; O Lohi; T Lundán; J M L Martí; M M Majumder; A Parsons; T Pemovska; H Rajala; K Vettenranta; O Kallioniemi; S Mustjoki; K Porkka; C A Heckman
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

Review 4.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

5.  RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.

Authors:  Valentina Gianfelici; Sabina Chiaretti; Sofie Demeyer; Filomena Di Giacomo; Monica Messina; Roberta La Starza; Nadia Peragine; Francesca Paoloni; Ellen Geerdens; Valentina Pierini; Loredana Elia; Marco Mancini; Maria Stefania De Propris; Valerio Apicella; Gianluca Gaidano; Anna Maria Testi; Antonella Vitale; Marco Vignetti; Cristina Mecucci; Anna Guarini; Jan Cools; Robin Foà
Journal:  Haematologica       Date:  2016-05-05       Impact factor: 9.941

6.  Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Authors:  A Lonetti; I L Antunes; F Chiarini; E Orsini; F Buontempo; F Ricci; P L Tazzari; P Pagliaro; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

7.  CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.

Authors:  L M Sarmento; V Póvoa; R Nascimento; G Real; I Antunes; L R Martins; C Moita; P M Alves; M Abecasis; L F Moita; R M E Parkhouse; J P P Meijerink; J T Barata
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

8.  Development of Selective Covalent Janus Kinase 3 Inhibitors.

Authors:  Li Tan; Koshi Akahane; Randall McNally; Kathleen M S E Reyskens; Scott B Ficarro; Suhu Liu; Grit S Herter-Sprie; Shohei Koyama; Michael J Pattison; Katherine Labella; Liv Johannessen; Esra A Akbay; Kwok-Kin Wong; David A Frank; Jarrod A Marto; Thomas A Look; J Simon C Arthur; Michael J Eck; Nathanael S Gray
Journal:  J Med Chem       Date:  2015-08-18       Impact factor: 7.446

Review 9.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.

Authors:  Geoffrey Shouse; Liana Nikolaenko
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 10.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.